IRVINGTON, N.Y., Oct. 21, 2013 (GLOBE NEWSWIRE) -- MELA Sciences, Inc. (Nasdaq:MELA), a leader in the fight against melanoma with MelaFind®, the first and only FDA approved optical diagnostic device for melanoma detection used by dermatologists, today announced the results of four studies which were displayed in poster presentations at the Fall Clinical Dermatology Conference which took place from October 17 – 20, 2013 in Las Vegas, Nevada. MELA Sciences also held its first Clinical Advisory meeting where the company announced the launch of a new user study called the MelaFind Experience Trial (MET-1).
Help employers find you! Check out all the jobs and post your resume.
